Peptide guides & research articles
Research-use-only explainers and comparisons to help you understand the compounds you work with.
BPC-157 vs TB-500: Research Recovery Peptides Compared
A research comparison of BPC-157 and TB-500 (Thymosin Beta-4 fragment): their origins, mechanisms (angiogenesis and tendon effects vs actin-binding and cell migration), and why researchers study them together as a blend.
Read article →CJC-1295 vs Ipamorelin vs Sermorelin: Growth Hormone Secretagogues Compared
A research comparison of CJC-1295, Ipamorelin, and Sermorelin — GHRH analogs vs a ghrelin-mimetic GHRP — covering DAC vs no-DAC half-life, the common CJC-1295 + Ipamorelin research pairing, and selectivity in research contexts.
Read article →Exploring Slower Titration Schedules in GLP-1 Agonist Therapy for Enhanced Tolerability
Discover the benefits of slower titration schedules in GLP-1 agonist therapy for improved tolerability in research contexts. Insights from studies like SURMOUNT
Read article →Exploring the Impact of GLP-1, GIP, and Glucagon Triple Agonism on Energy Expenditure
A research-focused analysis of how GLP-1, GIP, and glucagon triple agonism influences energy expenditure, citing key studies and clinical trials.
Read article →How GLP-1, GIP and Glucagon Triple Agonism Affects Energy Expenditure: Mechanisms and Research Evidence
Explore how retatrutide's triple agonism of GLP-1, GIP, and glucagon receptors influences energy expenditure through brown fat activation, thermogenesis, and me
Read article →How Retatrutide Works: Triple Receptor Mechanism
An educational explainer on how retatrutide works — covering GLP-1, GIP, and glucagon receptor agonism and why combining all three may synergize for metabolic effect.
Read article →How to Reconstitute Peptides: A Step-by-Step Research Guide
A step-by-step research guide to reconstituting lyophilized peptides with bacteriostatic water, including BAC water volume calculation, injection technique, swirling, and storage — using BPC-157 as a worked example.
Read article →Investigating Retatrutide: The TRIUMPH Phase 3 Clinical Trial Program
An in-depth look at the TRIUMPH phase 3 program testing retatrutide, a novel GLP-1 receptor agonist for obesity and metabolic research.
Read article →Investigating Retatrutide Titration and GI Tolerability in Preclinical Research
Research-focused analysis of retatrutide titration protocols and gastrointestinal tolerability in preclinical studies, with references to key findings from Jast
Read article →Long-Term Effects and Maintenance Strategies of Weight-Loss Treatments Beyond the Initial Year
Explore the long-term effects and maintenance strategies of weight-loss treatments, focusing on research with retatrutide and GLP-1 peptides, supported by clini
Read article →Retatrutide and Lean Mass Preservation During Weight Loss: Research Evidence
Explore research on retatrutide's effects on lean mass preservation during weight loss, including body composition data from clinical trials and mechanisms.
Read article →Retatrutide and Lean Mass Preservation: Insights from Research
Explore the role of retatrutide in preserving lean mass during weight loss, with insights from key studies and GLP-1 class peptide research. Research-use-only.
Read article →Retatrutide Clinical Trial Results: Phase 2 Deep Dive
A detailed review of the Jastreboff 2023 NEJM Phase 2 retatrutide trial — dose cohorts, 48-week outcomes, adverse events, and what the data means for Phase 3.
Read article →Retatrutide Dosing Protocol: What Phase 2 Shows
A research-focused summary of the retatrutide dose escalation schedule used in Phase 2 trials — titration rationale, GI adverse event relationship, and research context.
Read article →Retatrutide Phase 3 Trials: The TRIUMPH Program
What researchers know about the retatrutide Phase 3 TRIUMPH program as of 2024 — trial design, cardiovascular outcomes, expected timelines, and key questions for the field.
Read article →Retatrutide vs Tirzepatide: Mechanisms Compared
A research-focused comparison of retatrutide and tirzepatide, examining dual vs triple receptor agonism and Phase 2 vs Phase 3 weight loss trial outcomes.
Read article →Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Receptor Agonists Compared
A research comparison of semaglutide, tirzepatide, and retatrutide — single GLP-1 vs dual GIP/GLP-1 vs triple GIP/GLP-1/glucagon agonism — and the key weight-loss figures from STEP 1, SURMOUNT-1, and the retatrutide Phase 2 trial.
Read article →The Role of Strength Training in Preserving Muscle Mass During Weight Loss Plateaus on GLP-1 Therapy
Explore how strength training aids in maintaining muscle mass during weight loss plateaus on GLP-1 therapy, supported by research insights and clinical trials.
Read article →Understanding Retatrutide's Impact on Hepatic Fat and Metabolic Markers: A Research Perspective
Explore the latest research on retatrutide's effects on hepatic fat and metabolic markers, focusing on GLP-1 class peptides and their implications for metabolic
Read article →